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Abstract
Introduction
Mycobacterium ulcerans (M. ulcerans) is a necrotizing skin infection endemic to the Bellar-
ine Peninsula, Australia. Current treatment recommendations include 8 weeks of combina-
tion antibiotics, with adjuvant surgery if necessary. However, antibiotic toxicity often
results in early treatment cessation and local experience suggests that shorter antibiotic
courses may be effective with concurrent surgery. We report the outcomes of patients in the
Barwon HealthM. ulcerans cohort who received shorter courses of antibiotic therapy than
8 weeks.
Methodology / Principal findings
A retrospective analysis was performed of allM. ulcerans infections treated at Barwon
Health from March 1, 1998 to July 31, 2013. Sixty-two patients, with a median age of
65 years, received< 56 days of antibiotics and 51 (82%) of these patients underwent con-
current surgical excision. Most received a two-drug regimen of rifampicin combined with ei-
ther ciprofloxacin or clarithromycin for a median 29 days (IQR 21–41days). Cessation rates
were 55% for adverse events and 36% based on clinician decision. The overall success
rate was 95% (98% with concurrent surgery; 82% with antibiotics alone) with a 50% suc-
cess rate for those who received< 14 days of antibiotics increasing to 94% if they received
14–27 days and 100% for 28–55 days (p<0.01). A 100% success rate was seen for
concurrent surgery and 14–27 days of antibiotics versus 67% for concurrent surgery and
< 14 days of antibiotics (p = 0.12). No previously identified risk factors for treatment failure
with surgery alone were associated with reduced treatment success rates with
< 56 days of antibiotics.
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Conclusion
In selected patients, antibiotic treatment durations forM. ulcerans shorter than the current
WHO recommended 8 weeks duration may be associated with successful outcomes.
Author Summary
Buruli ulcer is a necrotizing skin and subcutaneous tissue infection caused byMycobacteri-
um ulcerans and is the third most common mycobacterial infection, behind tuberculosis
and leprosy, world-wide. In recent years, the World Health Organisation has modified its
guidelines forM. ulcerans treatment, moving from predominantly surgical to predomi-
nantly medical based management. It now recommends the combination of oral rifampi-
cin and intramuscular streptomycin for a period of eight weeks as first-line therapy, with
surgery as adjunctive therapy if necessary. The Barwon Health experience from south-
eastern Australia has demonstrated that the entirely oral combination of rifampicin with
either ciprofloxacin or clarithromycin for eight weeks can be an effective treatment option.
However, these antibiotics are often toxic leading to early cessation, especially in the elder-
ly. In addition, clinicians have been using a shorter duration of therapy for smaller lesions
that have also been surgically managed. This study reviews our experience treating
M. ulcerans with antibiotic durations of less than 8 weeks and demonstrates that successful
outcomes can be achieved in selected patients, with success rates influenced by the dura-
tion of treatment and the use of surgical excision. This finding needs confirmation in fur-
ther studies, but could have significant benefits in terms of reducing toxicity and
improving adherence associated with Buruli ulcer antibiotic treatment.
Introduction
Mycobacterium ulcerans (M. ulcerans) infection, or Buruli ulcer, is a necrotizing infection of
the skin and subcutaneous tissue and is the third most common mycobacterial infection in
immunocompetant people after tuberculosis and leprosy. It has been reported in 33 predomi-
nantly subtropical and tropical countries, with west and central Africa being the worst affected
regions [1]. In Australia endemic foci of infection are found in tropical Far North Queensland
and temperate regions of southern Victoria [2].
Up until 2004, the World Health Organisation (WHO) recommended wide surgical exci-
sion as treatment forM. ulcerans lesions, with no role for antibiotics which were thought to be
ineffective [3]. However surgical treatment was often difficult to access in resource-limited set-
tings [4], was limited by high recurrence rates [5, 6] and in severe cases caused significant cos-
metic morbidity and increased costs [7, 8]. Mounting clinical evidence of the effectiveness of
antibiotics [9–14] has resulted in a paradigm shift to a predominantly medical approach. The
latest WHO recommendations are for eight weeks combination antibiotic therapy with intra-
muscular streptomycin and oral rifampicin. Surgical intervention is recommended only to has-
ten healing of more extensive ulcers, if antibiotics are contraindicated or not tolerated, or at a
patient’s request. In addition, if surgery is required, an initial four weeks of antibiotics prior to
surgery is recommended [2, 15].
Clinicians at Barwon Health began using antibiotics to treatM. ulcerans infections from the
Bellarine Peninsula in 1998 [5]. Since this time the proportion of patients receiving antibiotics
has increased, resulting in fewer recurrences and permitting more conservative, and thus less
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reconstructive, surgery [12]. Oral antibiotics have subsequently reduced hospitalisations and
the cost of treatment [7]. Our current treatment practice for the majority ofM. ulcerans lesions
is an oral combination of rifampicin with either ciprofloxacin or clarithromycin for eight
weeks. Surgery is used for debriding necrotic wounds or closing large tissue defects to increase
the rate of wound healing, for patients unable or unwilling to take antibiotics, and for those
preferring the more rapid healing of small lesions that surgical excision and direct closure en-
ables compared with the often prolonged healing of lesions treated with antibiotics alone [2].
However, these protracted antibiotic treatment regimens are not without toxicity, and 16–
33% of patients, often elderly, cease them early due to side effects [12, 13]. In addition, shorter
courses of adjunctive antibiotics (4–6 weeks) have been offered for smaller lesions treated with
surgical excision and direct closure based on previous experience where cure was obtained for
100% of 21 patients who received between 12 and 30 days of antibiotics combined with surgical
excision [12].
The aim of this study was to review the experience and outcomes of patients in the Barwon
HealthM. ulcerans observational cohort who received a shorter course of antibiotic therapy
than the standard recommended duration of 8 weeks.
Methods
A retrospective analysis was performed of all confirmedM. ulcerans infections treated at Bar-
won Health from March 1, 1998 to July 31, 2013. Data was collected prospectively using Epi-
info 6 (CDC Atlanta, USA). Definitions used for the study can be found in Table 1.
Patients who had received antibiotics forM. ulcerans were included in the study. Treatment
duration was separated into 56 days (long-course therapy), and< 56 days (short-course
therapy). Patients were followed for 12 months after the cessation of treatment. Drug dosages
for adults included rifampicin 10 mg/kg/day (up to a maximum of 600 mg daily), ciprofloxacin
500 mg twice daily, moxifloxacin 400 mg once daily, clarithromycin 500 mg twice daily and
Table 1. Parameter deﬁnitions used during analysis.
Item Deﬁnition
M. ulcerans case Lesion clinically consistent with M. ulcerans PLUS
- Positive M. ulcerans PCR or culture* from a swab, biopsy or excised lesion
- Histopathology of an excised lesion showing a necrotic ulcer with the presence
of acid-fast bacilli consistent with acute M. ulcerans infection
Surgical deﬁnitions - Major surgery: closure of an excised lesion using a split skin or full thickness
skin graft or vascularised tissue ﬂap
- Positive margins: histology of excised tissue showing granulomatous
inﬂammation or necrotic tissue extending to the tissue margins
Long-course
antibiotics
Duration of antibiotics  56 days
Short-course
antibiotics
Duration of antibiotics < 56 days
Treatment success Healing of the entire lesion without recurrence 12 months after the antibiotic
treatment course had been completed.
Treatment failure A recurrent M. ulcerans lesion within 12 months of treatment completion that was
either a) culture positive for M. ulcerans or b) had histopathology showing a necrotic
ulcer with the presence of acid-fast bacilli consistent with acute M. ulcerans and did
not show evidence of a paradoxical reaction
*Mycobacterial cultures were performed using Lowenstein–Jensen media and incubated for 12 weeks
doi:10.1371/journal.pntd.0003503.t001
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ethambutol 15 mg/kg/day. A complication of medical therapy was defined as an adverse event
attributed to an antibiotic that required its cessation. Immune suppression was defined as cur-
rent treatment with immunosuppressive medication (eg. prednisolone) or active malignancy.
The position of aM. ulcerans lesion was described as distal if it was on or below the elbow
or knee.
Surgical specimens were sent to the Victorian Infectious Diseases Reference Laboratory
(VIDRL) for mycobacterial culture using Lowenstein-Jensen media and a 12-week
incubation period.
Data was analysed using STATA 13 (StataCorp, Texas, USA). The main variable assessed
was treatment outcome and defined as success or failure as outlined in Table 1. Proportions
were compared using 2x2 tables and the Chi-squared and Fisher’s exact test. Median values
were compared using the Mann-Whitney test.
Ethics
This is an observational, retrospective cohort study with analysis performed on anonymised
data. Verbal patient consent, or consent from a parent or guardian in the case of a minor, was
gained for collection of data and noted in the patient medical record. Barwon Health’s Human
Research and Ethic Committee have approved this analysis.
Results
Demographics
FromMarch 1, 1998 to July 31, 2013 there were 252 patients diagnosed withM. ulcerans infec-
tion at Barwon Health. Forty-one patients who were not treated with antibiotics were excluded
from this analysis, two were excluded due to unrelated deaths during follow-up and two were
lost to follow-up. Therefore 207 patients were included; 110 (53%) were male and the median
age was 59 years (IQR 36–75 years). Sixty-two (30%) patients received less than 56 days of anti-
biotic treatment (short-course therapy) whilst 145 (70%) patients had 56 days or more (long-
course therapy) (Table 2).
Comparisons of patient characteristics for short (n = 62) and long-course
(n = 145) antibiotic groups
Those receiving short-course antibiotics were more likely to be female, 60 years of age, have
WHO category 1 lesions, and were less likely to have had major surgery or have positive mar-
gins (Table 2). However there were no significant differences in the proportions that were dia-
betic, the type or site of lesions, or the duration of symptoms prior to diagnosis (Table 2).
Short-course treatment cohort (n = 62)
The median age of the patients was 65 years (range 2–94 years) and their lesion was present for
a median of 42 days prior to diagnosis (IQR, 24–70 days). Fifty-one (82%) patients had their le-
sions surgically excised, with the defect directly closed in 25 (49%) cases, and closed with split
skin grafts in 21 (41%), a vascularised tissue flap in 4 (8%) and both a split skin graft and a vas-
cularised tissue flap in 1 case (2%). Thirty-nine (76%) of those who had surgery had previously
commenced antibiotics for a median of 8 days (IQR, 4–18 days). Twenty of these patients had
specimens sent forM. ulcerans culture and their median duration of antibiotics prior to surgery
was 12 days (IQR 5–28 days). Six of these patients (30%) had positive mycobacterial cultures;
4 had received 8 days or less of antibiotics, one had received 17 days and one 18 days of antibi-
otics prior to surgery (Fig. 1).
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The regimens used were predominantly rifampicin-based in combination with ciprofloxacin
in 41 (66%), clarithromycin in 12 (19%), clarithromycin/ethambutol in 3 (5%) and moxifloxa-
cin in 2 (3%) patients. Other combinations included clarithromycin with either ethambutol in
2 patients (3%) or ciprofloxacin (1 patient; 2%) and clarithromycin alone in one patient (2%).
The median duration of treatment was 29 days (IQR 21–41 days). Cessation secondary to side
effects, often attributed to more than one of the drugs in a combination, occurred in 34 (55%)
patients. The most common side effects included nausea, vomiting, diarrhoea, hepatitis, rash,
Table 2. Baseline characteristics of patients receiving short-course (< 56 day) or long-course ( 56
days) antibiotics for M. ulcerans infection.
Short-course (n = 62) Long-course (n = 145) p value
Sex
Male 25 (40%) 85 (59%) p = 0.02
Female 37 (60%) 60 (41%)
Age
< 60 years 24 (39%) 80 (55%) p = 0.03
 60 years 38 (61%) 65 (45%)
Immune suppression
No 54 (87%) 137 (94%) p = 0.07
Yes 8 (13%) 8 (6%)
Diabetes
No 54 (87%) 133 (92%) p = 0.30
Yes 8 (13%) 12 (8%)
Type of lesion
Ulcerative 56 (90%) 121 (83%) p = 0.07
Nodular 5 (8%) 6 (4%)
Plaque 0 (0%) 2 (1%)
Oedematous 1 (2%) 16 (11%)
WHO category
1 57 (92%) 113 (77%) p = 0.003
2 0 (0%) 24 (17%)
3 5@ (8%) 9 (6%)
Lesion Position
Proximal 10 (16%) 13 (9%) p = 0.13
Distal 52 (84%) 133 (91%)
Duration of symptoms prior to diagnosis*
 75 days 46 (78%) 110 (77%) p = 0.92
> 75 days 13 (22%) 32 (23%)
Positive margins#
No 23 (48%) 15 (19%) p<0.001
Yes 25 (52%) 65 (81%)
Major surgery&
No 25 (49%) 25 (30%) p = 0.03
Yes 26 (51%) 57 (70%)
@ 1 patient with an oedematous lesion, 3 patients with 2 lesions and 1 patient with 13 lesions
*n = 200 (missing data in 7 patients)
#n = 128
&n = 133
doi:10.1371/journal.pntd.0003503.t002
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joint aches and acute renal failure. In twenty-two (36%) patients the clinician’s decision to
cease treatment was based on presumed adequate treatment when combined with surgical
management of the lesions. Two patients ceased due to interactions with concomitant medica-
tions or patient’s wishes in each of the surgically treated and antibiotic only groups.
Overall treatment results (n = 62)
Fifty-nine of 62 (95%) short-course patients experienced treatment success, including the 5
WHO category 3 patients. Details of the three patients who failed treatment are listed in
Table 3. This compares with a 99% success rate (144/145) for patients who received long-
course treatment. Outcomes according to the duration of antibiotic treatment are presented in
Table 4 and Fig. 2. Overall, those who received less than 14 days of therapy had a 50% success
rate which increased to 94% if they received 14–27 days of treatment and 100% for 28–55 days
treatment (p<0.01; Table 4, Fig. 2A). The success rate for those receiving< 28 days compared
to 28 days was reduced (86% versus 100%, p = 0.04).
Fig 1. Red column-Negative tissue culture. Blue column-Positive tissue culture.
doi:10.1371/journal.pntd.0003503.g001
Table 3. Characteristics of patients who failed short-course antibiotic treatment for M. ulcerans infection.
Year Age/Sex Co-morbid Lesion Sx Abx Days Cessation reason Result
2001 79F Diabetes Distal leg ulcer No ClarithromycinEthambutol 7 Nausea Local recurrence
2002 73F Diabetes I/S^ Distal wrist nodule No Rifampicin Clarithromycin
Ethambutol
21 Hepatitis Local recurrence
2006 94F Nil noted Distal leg ulcer Yes* Rifampicin Ciproﬂoxacin 6 Nausea / diarrhoea Local and distal (ankle)
recurrence
Sx = surgery; Abx = antibiotics
^Immunosuppressed on prednisolone for eczema
*positive surgical margin
doi:10.1371/journal.pntd.0003503.t003
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Surgery plus antibiotics (n = 51)
There was a 98% (50/51 cases) treatment success rate in those receiving antibiotics and surgery
(Table 4, Fig. 2). Cure rates were significantly increased in those who received longer durations
of therapy (p<0.001). All 23 patients treated with antibiotics and surgery for 14–28 days
achieved treatment success, in comparison to 67% (2 patients) if they received antibiotics for
less than 14 days (p = 0.12). When only cases with positive margins were included the cure
rates remained higher for treatment durations of 14–28 days compared with< 14 days (8/8 pa-
tients versus 0/1 patients, p = 0.11).
Antibiotics alone (n = 11)
Although the numbers are small, there was an 82% (9/11 cases) success rate for those treated
with antibiotics alone. Cure rates were significantly increased in those who received a duration
of therapy greater than 28 days (p = 0.05). Two of three patients receiving antibiotics alone for
less than 28 days failed treatment, whilst the 6 patients receiving 28–42 days of treatment were
cured (p = 0.08; Table 4; Fig. 2B).
Success rates with respect to known risk factors for recurrence with
surgery alone
There were no significant differences in recurrence rates for those patients with positive mar-
gins, age 60 years, duration of symptoms> 75 days, immunosuppression or distal lesions
(Table 5).
Discussion
Our study suggests that an antibiotic treatment course forM. ulcerans infections of less than
the current WHO recommended of 8 weeks duration can be associated, in selected patients,
with good outcomes with a success rate of 95% overall and 98% in patients who received com-
bined medical and surgical therapy. However the effectiveness of short-course therapy was
influenced by the duration of antibiotics. Success rates of 100% were achieved after at least
28 days of antibiotics but this reduced to 94% if 14–27 days of antibiotics were used and only
50% if less than 14 days of antibiotics were used (p = 0.001).
Surgery may have also influenced success rates with improved results in those who received
antibiotics plus surgery compared to antibiotics alone. Although the numbers were small in the
Table 4. Proportion of patients achieving treatment success according to antibiotic treatment duration for M. ulcerans infection.
Days of antibiotic treatment p value
1–13 14–27 28–41 42–56
Overall (n = 62)
Treatment success 2 (50%) 17 (94%) 28 (100%) 12 (100%) 0.001
Treatment failure 2 (50%) 1 (6%) 0 (0%) 0 (0%)
Surgery + antibiotics (n = 51)
Treatment success 2 (67%) 16 (100%) 23 (100%) 9 (100%) 0.001
Treatment failure 1 (33%) 0 (0%) 0 (0%) 0 (0%)
Antibiotics alone (n = 11)
Treatment success 0 (0%) 1 (50%) 5 (100%) 3 (100%) 0.05
Treatment failure 1 (100%) 1 (50%) 0 (0%) 0 (0%)
doi:10.1371/journal.pntd.0003503.t004
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group treated with antibiotics alone (11 patients), it may be that shorter antibiotic treatment
courses are effective when there has been a reduction of bacterial load by surgery. This finding
needs to be further investigated in studies involving larger patient numbers.
These outcomes with increased patient numbers build on our previous findings from this
cohort of 100% treatment success in 21 patients receiving 12–30 days of antibiotics combined
with surgical excision [12]. The overall success rate of 98% in this study is similar to that re-
ported from our Barwon Health cohort treated with antibiotics alone for at least 56 days (36
Fig 2. A) Purple column-Positive margin / treatment failure.Green column-Unknownmargin / treatment success. Red column -Negative margin /
treatment success. Blue column-Positive margin / treatment success. B) Red column-Treatment failure. Blue column-Treatment success.
doi:10.1371/journal.pntd.0003503.g002
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patients; 97% success rate)[13] or at least 60 days of antibiotics plus surgery (44 patients; 100%
success rate) [12], and in the long-course group reported in this study (99%). This suggests that
in our observational cohorts similar success rates are possible for short-course treatment com-
pared to when antibiotics have been used for at least 56 days.
These success rates are also comparable to studies from African cohorts using 56 days of an-
tibiotics. In a randomised trial in Ghana, 8 weeks of rifampicin and streptomycin or 4 weeks of
rifampicin and streptomycin followed by 4 weeks of oral rifampicin and clarithromycin re-
ported no recurrences after 12 months in 147 patients [9]. In Benin an 8-week combination of
clarithromycin and rifampicin in 30 patients, with half undergoing surgery, resulted in no
treatment failures [10]. In a separate study in Ghana, 8 weeks of rifampicin and streptomycin
resulted in no recurrences at one year in 158 patients, of whom only 8 had adjunctive surgical
treatment [11]. Finally, in an observational trial in Ghana involving 43 patients with lesions
less than 15cm, using 2 weeks of rifampicin and streptomycin followed by 6 weeks of rifampi-
cin and clarithromycin, 93% had completely healed their lesions and there were no recurrences
out to one year [14].
Supportive evidence for the effectiveness of short-course treatment is provided by the inabil-
ity in our study to cultureM. ulcerans from surgical specimens taken after more than 18 days
of antibiotics (Fig. 1). Further Australian experience reported by Gordon and colleagues [16]
showed that excisional samples from 2 patients were culture negative after 4 or 6 weeks of ri-
fampicin combined with moxifloxacin or clarithromycin. Similar findings have also been re-
ported from aWHO-sponsored study of 21 African patients treated with oral rifampicin and
intramuscular streptomycin whereM. ulcerans could not be cultured from 11 excised lesions
after 4 weeks of antibiotic treatment [17]. Furthermore, all samples except one were culture
negative after 4 weeks of rifampicin and clarithromycin in 9 patients in Benin [10].
Of note however, in a recent study by Phillips and colleagues [14], where patients were treat-
ed with 2 weeks of rifampicin and streptomycin followed by 6 weeks or oral rifampicin and
clarithromycin, 3 out of 7 lesions were culture positive 12 weeks after initiation of treatment
and 4 weeks after cessation of therapy, albeit at a lower bacterial loads. However despite this all
the lesions healed and there were no recurrences at 12 months. Furthermore, Nienhuis and col-
leagues showed that 3 of 5 lesions healed without surgical debridement after being culture posi-
tive post treatment with 4 weeks of standard therapy followed by 4 weeks of rifampicin and
clarithromycin [9]. This suggests that sterilization of tissue cultures during antibiotic treatment
Table 5. Proportion of patients achieving treatment success for M. ulcerans infection in high-risk categories.
Parameter No per group No treatment success (%) p value
Positive surgical margins 25 24 (96) 0.33
Negative surgical margins 23 23 (100)
Age < 60 years 24 24 (100) 0.28
Age  60 years 38 35 (92)
Duration of symptoms  75 days 46 44 (96) 0.53
Duration of symptoms > 75 days 13 12 (92)
Immunosuppressed 6 5 (83) 0.27
Not immunosuppressed 56 54 (96)
Distal lesion 52 49 (94) 1.0
Proximal lesion 10 10 (100)
doi:10.1371/journal.pntd.0003503.t005
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may not be required to achieve successful treatment outcomes and this further supports the po-
tential for antibiotic treatment durations to be shortened. Spontaneous healing of lesions with-
out treatment has also been reported [18] and it may be possible that once antibiotics +/-
surgery have reduced the bacterial load the immune system can sterilize any
persisting infection.
In our study, the majority of patients in the short-course group were selected because of an-
tibiotic side-effects requiring a cessation in treatment. If severe side-effects relate to increased
serum antibiotic levels compared to those not experiencing such reactions, it is possible that
this may have contributed to enhanced microbiological efficacy and improved rates of cure
with a reduced antibiotic course.
A limitation of this study is its observational design where patients were not randomised
into short and long-course treatment groups. Therefore there were differences in baseline char-
acteristics between the groups that may have influenced outcomes. Firstly there was a higher
proportion of patients with WHO category 1 lesions in the short-course group. If smaller le-
sions with a lower bacterial load require less antibiotic treatment this may have positively influ-
enced outcomes in this group. Secondly the short-course group had a lower proportion of
patients with positive margins which may favour improved outcomes as they are associated
with a higher rate of failure in the absence of antibiotic treatment [19]. Conversely the short-
course group had a higher proportion of patients with immunosuppression and age> 60
years, which have been associated with an increased rate of surgical treatment failure in the ab-
sence of antibiotics and may have negatively affected outcomes in this group [19]. Of note in
our study, none of the factors associated with treatment failure for surgery alone were associat-
ed with treatment failure with the use of short-course compared to long-course antibiotic ther-
apy (Table 5). Furthermore the majority of patients received fluoroquinolone antibiotics in
combination with rifampicin and results therefore may not be generalisable to patients not re-
ceiving fluoroquinolone-containing regimens. Finally, the lack of randomization also means
that there may have been other unmeasured confounders that could have influenced outcomes.
Our study represents a selected subset group of patients from south-eastern Australia. The
results may not be generalisable to allM. ulcerans lesions and other settings such as Africa
where a higher proportion of patients present late with advanced disease (WHO category 2
and 3) [11], cohorts are younger, the proportion of ulcerative lesions is less, and there is an in-
cidence of HIV co-infection [20]. Nevertheless, based on our findings, we advocate for further
research into the effectiveness of shorter antibiotic regimens for the treatment ofM. ulcerans,
including prospective randomised trials comparing them against standard 8-week treatment
regimens. Shorter regimens could potentially include 4 weeks of antibiotics for surgically-
excised lesions and 6 weeks of antibiotics if they are used alone. If successful, this could have
significant benefits in terms of reducing toxicity and improving adherence associated with
M. ulcerans antibiotic treatment.
Conclusions
In selected patients, antibiotic treatment durations forM. ulcerans shorter than the current
WHO recommended 8 weeks duration may be associated with successful outcomes. Success
may be influenced by the duration of treatment and the use of surgical excision.
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